MacroGenics (MGNX) investor relations material

Company overview and pipeline

• Focuses on next-generation antibodies for cancer, with four clinical-stage programs across three modalities, including ADCs and multi-specific platforms.

• Utilizes proprietary DART and Trident platforms for t cell engagers and bispecifics, with some assets partnered with major pharma companies.

• Three molecules leverage the Cinefix ADC platform, with broad access due to early adoption and up to seven molecules possible.

• Portfolio includes both proprietary and partnered programs, with several approved and commercialized molecules.

• Cash and marketable securities total $177M, with a runway through 2027, bolstered by a $70M royalty monetization deal.

Key clinical programs and data

• Lorigirlimab, a PD-1/CTLA-4 bispecific, is in phase 1 for prostate and gynecologic cancers, showing a 26% ORR and 29% PSA response in late-line prostate cancer.

• Durability of response is notable, with some patients maintaining benefit for up to two years.

• Safety profile shows fewer severe immune-mediated events compared to traditional CTLA-4 agents, with only 1-2 grade 3 colitis cases in 120+ patients.

• Lorikeet study (prostate cancer) is fully enrolled, with a clinical update expected later this year; Lannett study (gynecologic cancers) is ongoing.

• ADC programs target B7-H3, ADAM9, and an undisclosed target, with phase 1 studies ongoing and IND submission for O30 planned next year.

Technology and competitive positioning

• Cinefix ADC platform enables site-specific conjugation and potent exoticon payload, offering higher potency and less susceptibility to resistance.

• Proprietary HydraSpace technology allows conjugation to hydrophobic payloads, improving drug characteristics.

• Internal data show strong in vivo efficacy and efficient internalization compared to competitors.

• Market validation for the Cinefix linker from other pharma alliances and phase 3 advancement by Innovent.

• ADC targets have broad expression across solid tumors, with competitive but non-exclusive market dynamics.